Antiviral Effect and Safety of Once Daily BI 201335 NA in Hepatitis C Virus Genotype 1 Infected Treatment-naive Patients for 12 or 24 Weeks as Combination Therapy With Pegylated Interferon-alpha 2a and Ribavirin (Randomised, Open Label, Phase II).
Phase of Trial: Phase II
Latest Information Update: 10 Sep 2015
At a glance
- Drugs Faldaprevir (Primary) ; Peginterferon alfa-2a; Ribavirin
- Indications Hepatitis C
- Focus Therapeutic Use
- Acronyms SILEN-C3
- Sponsors Boehringer Ingelheim Pharmaceuticals
- 16 Feb 2013 Planned patient number is 140 according to European Clinical Trials Database record.
- 08 Nov 2011 Results presented at the 62nd Annual Meeting of the American Association for the Study of Liver Diseases.
- 08 Nov 2011 Additional results were presented at the 62nd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), according to a Boehringer Ingelheim media release.